AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

RNA-based Ovarian Cancer Diagnostic

Technology Benefits: Advantages of this approach include the ability to: detect ovarian cancer in the asymptomatic phase of the disease;use tissue samples that are routinely collected in a gynecologic exam; anddetect at high sensitivity (a few tumor cells).

Technology Application: Early detection of ovarian cancer

Detailed Technology Description: UC Inventors have discovered a number of mRNA transcripts that are selectively expressed in ovarian tumors and may be used to detect the presence of an ovarian tumor in a Pap smear and/or endometrial biopsy.

Application No.: 20170342504

Others: State Of Development
A number of ovarian tumor-specific transcripts have been identified and relevant primers developed. Work is continuing to identify additional tumor-specific transcripts and to optimize primers for detection in the relevant tissues.

Intellectual Property Info
Worldwide rights available; Pending patents available under confidentiality.

Related Materials
Cramer et al., Ovarian cancer biomarker performance in prostate, lung, colorectral, and ovarian cancer screening trial specimens, 2011; Cancer Prev Res (Phila), 4(3):365-74.
Zhu et. al., A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer, 2011, Cancer Prev Res (Phila), 4(3):375-83

Tech ID/UC Case
24303/2014-349-0

Related Cases
2014-349-0

*Abstract: Ovarian cancer is the fifth leading cause of cancer death among women in the US and the poor prognosis is related to the reality that the disease is not usually detected until a patient is in the advanced stages of the disease. Because there is an unmet need, some markers (e.g., Cancer Antigen 125 (CA125) and human epididymis protein 4 (HE4)) are being investigated for their ability to monitor ovarian cancer but there is no available test that has proven to be effective for early detection of the disease. There remains a need for predictive biomarkers that are able to reliably detect disease in the asymptomatic phase.

*IP Issue Date: Nov 30, 2017

*Principal Investigator: Name: Christian Barrett
Department:

Name: Dennis Carson
Department:

Name: Kelly Frazer
Department:

Country/Region: USA

For more information, please click Here